




Quotient  
Sciences

# Quotient Sciences


Globally differentiated pharmaceutical drug  
development service provider

# GHO 2015 acquisition: High-growth, market leader with unique service offering


## Unique early drug development proposition



## Integrated UK presence



# “The Heavy Lifting”: 2015 – 2019 development under GHO ownership




# 2019 exit: Globally differentiated pharmaceutical drug development service provider



<p><b>5 Sites</b></p>  <p>State-of-the-art facilities</p>	<p><b>&gt;850 Employees</b></p>  <p>Deep scientific knowledge</p>	<p><b>Formulation and drug delivery</b></p>  <p>All types of dosage form</p>	<p><b>Clinical trial manufacturing</b></p>  <p>High potency capabilities</p>	<p><b>Commercial manufacturing</b></p>  <p>Niche and hard-to-make-products</p>	<p><b>2 clinical pharmacology centres</b></p>  <p>280 beds globally</p>	<p><b>Translational Pharmaceuticals</b></p>  <p>Proven to save money</p>
---	--	---	--	---	--	---

# Outsized investment return underpinned by strong growth fundamentals



<p><b>4</b> </p> <p>add-ons</p>	<p><b>3x</b> </p> <p>Order book</p>	<p><b>2x</b> </p> <p>Continental Footprint</p>	<p><b>+150</b> clients </p> <p><b>+200</b> molecules </p>	<p><b>+580</b> </p> <p>employees</p>
--	--	--	--	---

# Further global expansion opportunity for next stage of growth

